HC Wainwright Predicts SOPHiA GENETICS Q2 Earnings

SOPHiA GENETICS SA (NASDAQ:SOPH) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for SOPHiA GENETICS in a report released on Monday, July 20th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.58) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.34 EPS and FY2030 earnings at $0.69 EPS.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Several other brokerages have also recently issued reports on SOPH. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $6.05 on Wednesday. The company has a market cap of $507.53 million, a P/E ratio of -11.63 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The stock has a 50-day moving average of $5.36 and a two-hundred day moving average of $5.07. SOPHiA GENETICS has a 1-year low of $2.92 and a 1-year high of $6.77.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Archon Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 1st quarter worth $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Insider Activity

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the sale, the chief executive officer owned 3,601,493 shares in the company, valued at $20,888,659.40. This represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 6,944 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $5.51, for a total value of $38,261.44. Following the completion of the sale, the chief technology officer directly owned 197,456 shares in the company, valued at $1,087,982.56. This represents a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 176,711 shares of company stock worth $959,913 over the last three months. Company insiders own 4.88% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $12 price target, suggesting meaningful upside from current levels if SOPHiA GENETICS can execute on its growth plan.
• Positive Sentiment: Longer-term HC Wainwright estimates turn positive, with FY2028, FY2029, and FY2030 forecast to move into profitability, which may support the stock’s long-term valuation.
• Neutral Sentiment: Zacks Research upgraded SOPHiA GENETICS to Hold, a signal that sentiment is improving somewhat but not enough to indicate a clear buy case.
• Negative Sentiment: HC Wainwright’s near-term EPS estimates remain negative through FY2026 and FY2027, reinforcing investor concern that SOPHiA GENETICS may need more time before sustained earnings improvement.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.